Skip to main content
PMC home page
Gut logoLink to Gut
. 1989 Nov;30(Spec No):22–28. doi: 10.1136/gut.30.spec_no.22

Intestinal permeability, non-steroidal anti-inflammatory drug enteropathy and inflammatory bowel disease: an overview.

I Bjarnason 1, T J Peters 1
PMCID: PMC1440693  PMID: 2691345

Full text

PDF
22

Images in this article

25Fig 2
on p.25

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berden J. H., Muytjens H. L., van de Putte L. B. Reactive arthritis associated with Campylobacter jejuni enteritis. Br Med J. 1979 Feb 10;1(6160):380–381. doi: 10.1136/bmj.1.6160.380-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bjarnason I., Macpherson A. The changing gastrointestinal side effect profile of non-steroidal anti-inflammatory drugs. A new approach for the prevention of a new problem. Scand J Gastroenterol Suppl. 1989;163:56–64. doi: 10.3109/00365528909091176. [DOI] [PubMed] [Google Scholar]
  3. Bjarnason I., O'Morain C., Levi A. J., Peters T. J. Absorption of 51chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease. Gastroenterology. 1983 Aug;85(2):318–322. [PubMed] [Google Scholar]
  4. Bjarnason I., Peters J. Helping the mucosa make sense of macromolecules. Gut. 1987 Sep;28(9):1057–1061. doi: 10.1136/gut.28.9.1057. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bjarnason I., Peters T. J., Levi A. J. Intestinal permeability: clinical correlates. Dig Dis. 1986;4(2):83–92. doi: 10.1159/000171140. [DOI] [PubMed] [Google Scholar]
  6. Bjarnason I., Peters T. J., Veall N. A persistent defect in intestinal permeability in coeliac disease demonstrated by a 51Cr-labelled EDTA absorption test. Lancet. 1983 Feb 12;1(8320):323–325. doi: 10.1016/s0140-6736(83)91628-8. [DOI] [PubMed] [Google Scholar]
  7. Bjarnason I., Smethurst P., Fenn C. G., Lee C. E., Menzies I. S., Levi A. J. Misoprostol reduces indomethacin-induced changes in human small intestinal permeability. Dig Dis Sci. 1989 Mar;34(3):407–411. doi: 10.1007/BF01536263. [DOI] [PubMed] [Google Scholar]
  8. Bjarnason I., Williams P., Smethurst P., Peters T. J., Levi A. J. Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine. Gut. 1986 Nov;27(11):1292–1297. doi: 10.1136/gut.27.11.1292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Bjarnason I., Williams P., So A., Zanelli G. D., Levi A. J., Gumpel J. M., Peters T. J., Ansell B. Intestinal permeability and inflammation in rheumatoid arthritis: effects of non-steroidal anti-inflammatory drugs. Lancet. 1984 Nov 24;2(8413):1171–1174. doi: 10.1016/s0140-6736(84)92739-9. [DOI] [PubMed] [Google Scholar]
  10. Bjarnason I., Zanelli G., Prouse P., Smethurst P., Smith T., Levi S., Gumpel M. J., Levi A. J. Blood and protein loss via small-intestinal inflammation induced by non-steroidal anti-inflammatory drugs. Lancet. 1987 Sep 26;2(8561):711–714. doi: 10.1016/s0140-6736(87)91075-0. [DOI] [PubMed] [Google Scholar]
  11. Bjarnason I., Zanelli G., Smith T., Prouse P., Williams P., Smethurst P., Delacey G., Gumpel M. J., Levi A. J. Nonsteroidal antiinflammatory drug-induced intestinal inflammation in humans. Gastroenterology. 1987 Sep;93(3):480–489. doi: 10.1016/0016-5085(87)90909-7. [DOI] [PubMed] [Google Scholar]
  12. Bywaters E. G. Historical aspects of the aetiology of rheumatoid arthritis. Br J Rheumatol. 1988;27 (Suppl 2):110–115. doi: 10.1093/rheumatology/xxvii.suppl_2.110. [DOI] [PubMed] [Google Scholar]
  13. Ebringer A. The cross-tolerance hypothesis, HLA-B27 and ankylosing spondylitis. Br J Rheumatol. 1983 Nov;22(4 Suppl 2):53–66. doi: 10.1093/rheumatology/xxii.suppl_2.53. [DOI] [PubMed] [Google Scholar]
  14. Edmonds J., Geczy A. F., Sullivan J. S., Prendergast J. K., Upfold L. I., Bashir H. V. Enteric bacteria and HLA-B27 associated cell surface modification in patients with seronegative spondarthritis. Br J Rheumatol. 1983 Nov;22(4 Suppl 2):75–82. doi: 10.1093/rheumatology/xxii.suppl_2.75. [DOI] [PubMed] [Google Scholar]
  15. Mielants H., Veys E. M., Cuvelier C., de Vos M. Ileocolonoscopic findings in seronegative spondylarthropathies. Br J Rheumatol. 1988;27 (Suppl 2):95–105. doi: 10.1093/rheumatology/xxvii.suppl_2.95. [DOI] [PubMed] [Google Scholar]
  16. Prendergast J. K., Sullivan J. S., Geczy A., Upfold L. I., Edmonds J. P., Bashir H. V., Reiss-Levy E. Possible role of enteric organisms in the pathogenesis of ankylosing spondylitis and other seronegative arthropathies. Infect Immun. 1983 Sep;41(3):935–941. doi: 10.1128/iai.41.3.935-941.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Schwimmbeck P. L., Yu D. T., Oldstone M. B. Autoantibodies to HLA B27 in the sera of HLA B27 patients with ankylosing spondylitis and Reiter's syndrome. Molecular mimicry with Klebsiella pneumoniae as potential mechanism of autoimmune disease. J Exp Med. 1987 Jul 1;166(1):173–181. doi: 10.1084/jem.166.1.173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Svartz N. Sulfasalazine: II. Some notes on the discovery and development of salazopyrin. Am J Gastroenterol. 1988 May;83(5):497–503. [PubMed] [Google Scholar]
  19. Walker W. A., Isselbacher K. J. Uptake and transport of macromolecules by the intestine. Possible role in clinical disorders. Gastroenterology. 1974 Sep;67(3):531–550. [PubMed] [Google Scholar]
  20. Wands J. R., LaMont J. T., Mann E., Isselbacher K. J. Arthritis associated with intestinal-bypass procedure for morbid obesity. Complement activation and characterization of circulating cryoproteins. N Engl J Med. 1976 Jan 15;294(3):121–124. doi: 10.1056/NEJM197601152940301. [DOI] [PubMed] [Google Scholar]
  21. Warren C. P. Arthritis associated with Salmonella infections. Ann Rheum Dis. 1970 Sep;29(5):483–487. doi: 10.1136/ard.29.5.483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Zaphiropoulos G. C. Rheumatoid arthritis and the gut. Br J Rheumatol. 1986 May;25(2):138–140. doi: 10.1093/rheumatology/25.2.138. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES